A further point is the description of LVHT as a congenital condition. Though presumably correct for most of the cases, LVHT may not only be congenital, but also acquired, which means that LVHT either develops after birth (truly acquired) or is masked because of severe LV dilatation or thickening (hidden LVHT) [2, 3] . When was LVHT actually detected in the presented patient? Was LVHT detected already before ablation 1? Were echocardiographies carried out before ablation 1?
A third point concerns the cause of LVHT. Nothing is mentioned if the patient carried any of the known mutations in genes so far reported in association with LVHT, such as TAZ, DTNA, ZASP, lamin A/C, MYH7, MYH7B, ACTC1, TNNT2, TNNI3, MYBPC3, TPM1, dystrophin, DMPK, ZNF9, LAMP2, GAA, mtDNA genes, AMPD1, GBE1, RYR1, COL7A1, PMP22, MMACHC, beta-globin, and DNAJC19 [Finsterer et al., submitted] . In this respect the authors should provide information if there was any indication of a neuromuscular disease or a chromosomal abnormality, conditions frequently associated with LVHT [4] .
A fourth point is the familiarity of LVHT. Since LVHT is frequently associated with genetic defects, it is also frequently familial [5] . The authors should also mention if there was previous stroke or embolism since the patient was 67 y at diagnosis of LVHT and assuming that LVHT was truly congenital it is quite likely that during such a long period a clinically manifesting or subclinical cerebrovascular embolic event had occurred. Did the patient ever undergo cerebral MRI to document old ischemic lesions in an embolic distribution?
Since cause and pathomechanism of LVHT are unknown, it is worthwhile to provide as much information as possible to clarify the many unsolved issues associated with LVHT. Though treatment of any complication of LVHT is symptomatic at the moment, deeper insight may give rise to the development of more causal therapeutic concepts.
